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Poor Prognostic Factors in Surgically Resected Stage I 
Non-small Cell Lung Cancer: Histopathologic and 
Immunohistochemical Analysis
Sukki  Cho,  M.D.,  Tae  In  Park,  M.D.,  Eung-Bae  Lee,  M.D.,  Ph.D.,  Shin-Ah  Son,  M.D.
Background:  A better understanding of the histopathology and molecular biology of lung cancer might improve our 
capability to predict the outcome for any individual patient. The purpose of this study was to evaluate several his-
topathologic and molecular markers in order to assess their prognostic value in stage I non-small cell lung cancer. 
Materials and Methods: One hundred ten patients at the Kyungpook National University Hospital were enrolled in 
the study. Histopathologic factors and molecular markers were selected. Results: Univariate analysis showed that 
the T stage, differentiation, visceral pleural invasion, and survivin expression were significantly associated with 
recurrence. Multivariate analysis demonstrated that differentiation and survivin overexpression emerged as in-
dependent prognostic factors of recurrence. Conclusion: In resected stage I non-small cell lung cancer, poor differ-
entiation and survivin overexpression have been identified as independent predictors of poor disease-free survival.
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INTRODUCTION
Lung cancer is the most common cause of cancer mortality 
worldwide. Non-small cell lung cancer (NSCLC) accounts for 
approximately 80% of lung cancer cases and pathologic stage 
I  represents  the  fastest  growing  segment  due  to  the  use  of 
low-dose computed tomography for screening. Despite the po-
tential  benefits  of  surgical  resection,  the  5-year  survival  rate 
is  only  60%  to  70%  in  stage  I  patients,  predominantly  as  a 
result  of  the  development  of  distant  metastasis  [1,2]. 
Variation  in  survival  largely  reflects  the  heterogeneity  of  tu-
mor  biology,  with  some  tumors  having  more  aggressive 
growth  and  greater  metastatic  potential  than  others;  therefore, 
current  tumor  stage  alone  cannot  exactly  establish  the  prog-
nosis for these patients. New prognostic factors must be iden-
tified to help clinicians better assess the probability of surviv-
al  and  to  optimize  therapeutic  strategies  for  each  individual 
patient  with  pathologic  stage  I  lung  cancer.  Several  studies 
have  already  demonstrated  possible  prognostic  roles  for  sev-
eral  biological  factors  in  NSCLC  and  have  found  helpful 
tools  for  identifying  patients  with  a  poor  prognosis  [3-6]. 
Among  those  factors,  thyroid  transcription  factor  1  (TTF-1) Sukki Cho, et al
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expression, especially in adenocarcinoma, was  known to  be a 
prognostic factor as well as a differential diagnostic factor be-
tween  primary  lung  cancer  and  other  adenocarcinoma  [7]. 
Nuclear  survivin  expression  might  be  an  independent  bio-
marker  for  disease  recurrence  and  survival  for  NSCLC  [8]. 
Epidermal growth factor receptor (EGFR) overexpression may 
predict  shorter  survival  in  patients  with  resected  stage  I-IIIA 
NSCLC,  although  this  is  under  debate  [9].  E-cadherin  is 
known  to  play  a  role  in  tumor  progression  and  distant  meta-
stasis;  therefore,  reduced  E-cadherin  expression  could  poten-
tially  affect  tumor  differentiation  and  prognosis  [10,11].  As  a 
result,  the  stratification  of  patients  without  lymph  node  in-
volvement,  according  to  prognostic  risk,  might  aid  in  select-
ing a group of high-risk patients who would benefit from ad-
juvant  therapy.
The purpose of this study is to evaluate several histopatho-
logic  variables  and  a  panel  of  molecular  markers-TTF-1,  sur-
vivin,  EGFR,  and  E-cadherin  expression-in  order  to  assess 
their  prognostic  value  and  their  combined  effects  on  re-
currence  in  patients  with  resected  stage  I  NSCLC.
MATERIALS AND METHODS
1) Patient characteristics
Between  January  2003  and  December  2006,  a  total  of  110 
patients  (84  male,  26  female)  with  resected  stage  I  NSCLC 
including  squamous  cell  carcinoma  (SCC),  adenocarcinoma 
(AC),  and  bronchioalveolar  carcinoma  (BAC)  were  enrolled 
in  the  study.  All  patients  in  the  study  underwent  potentially 
curative  surgery  consisting  of  lobectomy  including  sleeve  re-
section  and  bilobectomy  (n=104),  pneumonectomy  (n=4),  or 
segmentectomy  (n=2)  and  complete  mediastinal  lymph  node 
dissection.  None  of  the  patients  had  neoadjuvant  therapy. 
Patients  who  died  within  one  month  after  surgery  were  ex-
cluded  from  the  study  to  avoid  the  bias  of  perioperative 
mortality. The age of the patients ranged from 41 to 79 years 
(mean,  62.3  years).  Postsurgical  pathologic  tumor-node-meta-
stasis  (TNM)  staging  was  determined  according  to  the  guide-
lines  of  the  American  Joint  Cancer  Committee  (AJCC)  6th 
edition. There were 38 cases with stage IA (T1N0M0) and 72 
cases  with  stage  IB  (T2N0M0).  Follow-up  data  on  the  study 
population  were  obtained  by  direct  contact.  Follow-up  oc-
curred  at  3-month  intervals  for  the  initial  2  years  and  at 
4-month  intervals  thereafter.  Recurrences  were  detected  by 
computed tomography scans or positron emission tomography 
and, if necessary, confirmed by pathologic examination of bi-
opsy  specimens.  Patients  were  categorized  as  alive  with  evi-
dence  of  disease  or  alive  without  disease.  No  patient  in  this 
series died of cancer-unrelated causes. The time from the date 
of  the  operation  to  the  date  of  follow-up  or  death  was 
recorded. Local recurrence was defined as tumor recurrence at 
the ipsilateral lung or lymph node, and distant recurrence was 
defined as tumor recurrence at the contralateral lung or lymph 
node  and  a  distant  organ  such  as  the  liver,  brain,  or  bone.
2) Pathologic criteria
One  pathologist  (TIP)  reviewed  all  the  histologic  slides  in 
a  blind  fashion.  Tumor  samples  were  fixed  in  10%  buffered 
formalin, dehydrated, and embedded in paraffin. Then, 4 μL- 
thick  sections  were  cut  and  stained  with  hematoxylin  and 
eosin. Pathologic features were classified according to the his-
tologic criteria of the World Health Organization. The degree 
of differentiation was divided into three groups: good, moder-
ate,  and  poor.  Tumor  necrosis  (negative, ＜10%;  positive, ≥
10%)  and  visceral  pleural  invasion  (absent  vs.  present)  were 
noted. Tumor size (≤2 cm, 2＜ & ≤3 cm, 3＜ & ≤5 cm, 5＜ 
&  ≤7  cm,  ＞7  cm)  was  also  recorded.
3) Immunohistochemical methods
Briefly,  tissues  were  deparaffinized  in  xylene  and  rehy-
drated  in  graded  alcohols  and  water.  Endogenous  peroxidase 
was  blocked  by  soaking  in  3%  H2O2 a t  4 5
oC  for  4  minutes. 
The  slides  were  microwaved  in  citrate  buffer  (2.1  g/L,  pH 
6.0) at 120
oC for 15 minutes to unmask the antigen and were 
then treated with a protein-blocking reagent before incubation 
at  4
oC  overnight  with  primary  antibodies  at  a  1:50  dilution, 
as recommended by the supplier. After extensive washing, the 
sections  were  incubated  at  room  temperature  for  10  minutes 
with  biotinylated  anti-mouse  immunoglobulin  antibodies  (Zymed, 
San Francisco, CA, USA) at a 1:20 dilution and subsequently 
with  streptavidin-biotin  peroxidase  complexes  at  a  1:25  dilu-
tion.  The reaction products were visualized  by  immersing the 
slides in 3,3'-diaminobenzidine tetrahydrochloride. Countersta-
ining  was  performed  with  hematoxylin.  All  series  included Poor Prognostic Factors in Surgically Resected Stage I Non-small Cell Lung Cancer
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Table 1. Histopathologic findings in resected stage I non-small 
cell lung cancer (n=110)
Characteristics No.  of  patients  (%)
Cell  type
SCC
AC
BAC
T  stage
1
2
Tumor  size  (cm)
≤3
＞3
Differentiation
Good
Moderate
Poor
Necrosis
Absent
Present
Visceral  pleural  invasion
Absent
Present
69  (62.7)
37  (33.6)
4  (3.7)
38  (34.5)
72  (65.5)
59  (53.6)
51  (46.4)
33  (30.0)
60  (54.5)
17  (15.5)
77  (70.0)
33  (30.0)
58  (52.7)
52  (47.3)
SCC=squamous  cell  carcinoma;  AC=adenocarcinoma;  BAC= 
bronchioalveolar  carcinoma.
positive  and  negative  controls.  The  negative  controls  were 
prepared  by  omitting  the  primary  antibodies  and  known  pos-
itive  controls  were  included  in  each  run.
4) Evaluation of immunohistochemical data
TTF-1 staining was assessed by the intensity relative to the 
strong  staining  intensity  of  type  II  pneumocytes  as:  negative 
(absent  staining,  0),  low  expression  (weak  staining  intensity, 
1),  medium  expression  (intermediate  staining  intensity,  2),  or 
high  expression  (strong  staining  intensity,  3),  and  only  nu-
clear  staining  was  considered  positive  staining.  Positivity  was 
defined  as  a  staining  intensity  of  2  and  3.  EGFR  expression 
was  assessed  by  an  intensity  of  staining  from  0  to  3  and 
graded  as  normal  (0  and  1)  and  overexpressed  (2  and  3). 
E-cadherin  was  assessed  by  the  percentage  of  positive  tumor 
cells  as  follows:  0,  negative;  1＋,  ＜10%;  2＋,  10%−50%; 
3＋,  ＞50%,  and  was  regarded  as  lost  (＜10%  of  cytoplas-
mic staining) or preserved (≥10%). Survivin staining was as-
sessed in 5 to 10 high powered fields at 400×  magnification. 
Cytoplasmic  immunoreactivity  was  evaluated  semiquantitia-
tively  based  on  the  intensity  of  staining.  The  percentage  of 
positive  tumor  cells  was  evaluated  as  negative,  no  survivin 
cytoplasmic  staining;  1＋ (weak),  ＜25%  staining;  2＋ (mo-
derate),  25%−50%  staining;  and  3＋ (intense),  more  than 
50%  cytoplasmic  staining.  Positive  survivin  immunoreactivity 
was  accepted  as  a  positive  staining  area  of  more  than  25%.
5) Statistical analysis
The chi-square test and Fisher’s exact test were used to an-
alyze  the  association  between  histopathologic  variables,  mo-
lecular variables, and recurrence. The time to relapse was de-
fined  as  the  period  ranging  from  the  date  of  surgery  to  the 
date  when  relapse  was  diagnosed.  The  specific  time  to  re-
currence curves were plotted using the Kaplan-Meier method, 
whereas  the  log-rank  test  was  used  to  assess  the  statistical 
significance  of  differences  between  groups.  Multivariate  anal-
yses  were  performed  using  the  Cox  proportional  hazards 
model  to  identify  independent  prognostic  factors.  The  crite-
rion  for  significance  was  p＜0.1.
RESULTS
1) Histopathology (Table 1)
The  histological  type  of  NSCLC  was  as  follows:  69  cases 
of  SCC;  37  cases  of  AC;  4  cases  of  BAC.  The  average  tu-
mor  size  was  35.1±2 2 . 9  m m  w i t h  a  r a n g e  o f  3 −130  mm 
and that of 51 (46.4%) patients was over 30 mm. Thirty-three 
tumors  (30.0%)  were  good-,  60  (54.5%)  were  moderate-,  and 
17 (15.5%) were poor-differentiated. Visceral pleural invasion 
was  found  in  52  tumors  (47.3%)  and  33  tumors  (30.0%) 
showed  necrosis.  Thirty-one  (28.2%)  patients  had  tumors  of 
at  least  3  cm  in  size  as  well  as  visceral  pleural  invasion 
tumors.
2) Immunohistochemical staining (Table 2)
TTF-1  expression  was  detected  in  34  (30.9%)  patients. 
EGFR  overexpression  was  found  in  54  (49.1%)  of  the 
patients.  E-cadherin  was  lost  in  10  (9.1%)  cases.  Overex-
pression  of  survivin  was  observed  in  38  (34.5%)  patients.Sukki Cho, et al
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Table 2. Immunohistochemical staining in resected stage I 
non-small cell lung cancer (n=110)
Characteristics No.  of  patients  (%)
TTF-1
Negative
Positive
EGFR
a)
0
1
2
3
E-cadherin
a)
0
1
2
3
Survivin
a)
0 
1
2
3
76  (69.1)
34  (30.9)
39  (35.5)
17  (15.5)
31  (28.2)
23  (20.9)
5  (5.5)
5  (5.5)
28  (30.8)
53  (58.2)
37  (33.6)
35  (31.8)
36  (32.7)
2  (1.8)
TTF-1=thyroid  transcription  factor  1;  EGFR=epidermal  growth 
factor  receptor.
a)According  to  the  positive  area:  0  (＜25%),  1  (≥25%  & 
＜50%),  2  (≥50%  &  ＜75%),  and  3  (≥75%).
Table 3.  Association between histopathologic and molecular factors
Cell  type Differentiation
SCC AC p-value Good/moderate Poor p-value
TTF-1
    Negative
    Positive
EGFR
  N o r m a l
    Overexpression
E-cadherin
  L o s s
    Preserved
Survivin
  N o r m a l
    Overexpression
63  (91.3)
6  (8.7)
31  (44.9)
38  (55.1)
  7  (12.5)
49  (87.5)
44  (63.8)
25  (36.2)
12  (33.3)
24  (66.7)
20  (55.6)
16  (44.4)
3  (9.7)
28  (90.3)
25  (69.4)
11  (30.6)
0.000
-
0.076
-
0.760
-
0.783
-
65  (69.9)
28  (30.1)
44  (47.3)
49  (52.7)
7  (9.0)
71  (91.0)
63  (67.7)
30  (32.3)
11  (64.7)
  6  (35.3)
12  (70.6)
  5  (29.4)
  3  (23.1)
10  (76.9)
  9  (52.9)
  8  (47.1)
0.670
-
0.078
0.151
-
0.238
-
V a l u e s  a r e  p r e s e n t e d  a s  n u m b e r  ( % ) .
SCC=squamous  cell  carcinoma;  AC=adenocarcinoma;  TTF-1=thyroid  transcription  factor  1;  EGFR=epidermal  growth  factor  receptor.
3) Association between histopathologic and molecular 
factors (Table 3)
TTF-1  expression  was  significantly  high  in  several  factors 
such as AC (p=0.000) and visceral pleural invasion (p=0.032); 
however,  it  was  not  significantly  associated  with  differ-
entiation  (p=0.670).  The  EGFR  overexpression  was  more  fre-
quent  in  patients  with  SCC  (p=0.076).  Loss  of  E-cadherin 
was  correlated  with  larger  tumor  size  (p=0.061)  and  survivin 
(p=0.006,  no  expression).
4) Recurrence
The  disease  free  interval  was  determined  as  the  interval 
from the date of surgery to the date of first recurrence. Those 
without  recurrence  past  31  August  2010  were  classified  as 
censored.
Median  follow-up  was  55.0  (2.3−87.9)  months  and  the 
5-year disease free survival rate was 67.1%, with a mean dis-
ease  free  time  of  65.1  months.  Twenty-two  patients  (20.0%) 
had  recurrent  disease  and  15  patients  (13.6%)  died  from  dis-
ease-related  causes.  Seven  of  the  22  patients  had  local  re-
currence and 15 patients had distant recurrence. Of the 15 pa-
tients with distant metastasis, 5 patients had recurrence in the 
contralateral lung, 2 patients in the bone, 1 patient in the liv-
er,  1  patient  in  the  brain,  and  6  patients  in  multiple  sites. 
Table  4  shows  that  histopathologic  factors  including  differ-
entiation  (p=0.007),  visceral  pleural  invasion  (p=0.006),  T 
stage  (p=0.021),  and  molecular  markers  consisting  of  TTF-1 
negativity  (p=0.799)  and  survivin  expression  (p=0.088)  were 
associated  with  recurrence.  Table  5  lists  the  results  of  uni-Poor Prognostic Factors in Surgically Resected Stage I Non-small Cell Lung Cancer
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Table 4. Recurrence according to histologic factors and molecular 
markers
Characteristics
No.  of 
patients
Recurrence p-value
T  stage
1
2
Tumor  size  (cm)
≤3
＞3
Differentiation
Good
Moderate
Poor
Visceral  pleural  invasion
Absent
Present
TTF-1
Negative
Positive
EGFR
a)
Normal
Overexpression
E-cadherin
b)
Loss
Preserved
Survivin
c)
Normal
Overexpression
38
72
55
55
33
60
17
58
52
60
28
56
54
10
81
72
38
 3
19
 8
14
 5
10
 7
 6
16
16
 6
11
11
 1
19
11
11
0.021
0.153
0.059
0.006
0.799
0.924
0.304
0.088
TTF-1=thyroid  transcription  factor  1;  EGFR=epidermal  growth 
factor  receptor.
a)Negative=grade  0,1;  positive=grade  2,3. 
b)Loss=grade  0,1;  pre-
served=grade  2,3. 
c)Normal=grade  0,1;  overexpression=grade  2,3.
variate  analysis  for  the  prognostic  significance  of  each  histo-
pathologic factor and molecular marker in relation to the time 
to recurrence. The log rank test showed that the T stage, dif-
ferentiation,  visceral  pleural  invasion,  and  survivin  expression 
were  prognostic  factors  (Fig.  1).  By  multivariate  analysis  us-
ing  the  Cox  proportional  hazards  regression  model,  poor  dif-
ferentiation  and  survivin  expression  emerged  as  independent 
prognostic  factors  of  recurrence  (Table  6).
DISCUSSION
The  prognosis  for  patients  with  NSCLC  was  highly  varia-
ble  and  a  better  understanding  of  the  biology  of  tumors 
should  provide  useful  information  for  predicting  clinical  out-
comes  and  for  individualizing  treatment.  Because  lung  cancer 
is  a  heterogeneous  disease  resulting  from  the  acquisition  of 
multiple somatic  mutations,  the  prognostic  role  of histopatho-
logic and molecular markers is difficult to determine [12]. As 
a significant fraction of the patients at stage I experience dis-
ease  recurrence  and  die  after  a  curative  resection,  the  differ-
entiation  of  patients  with  a  high  risk  of  early  recurrence  and 
the  identification  of  patients  who  must  receive  adjuvant  ther-
apy  are  topics  of  great  interest  in  the  study  of  early  stage 
NSCLC.  However,  stratification  of  patient  prognoses  using 
only  the  TNM  staging  system  does  not  allow  one  to  differ-
entiate between patients with stage I lung cancer that are and 
are  not  at  risk  of  tumor  recurrence. It  has  been  demonstrated 
that adjuvant therapy is not effective in all patients with stage 
I disease; it is only effective in specific subsets of patients. It 
is important to select a subgroup of patients with stage I dis-
ease  that  might  benefit  from  adjuvant  therapy  and  for  this 
reason,  investigators  have  attempted  to  pinpoint  factors  that 
predict  poor  prognosis  through  analysis  of  clinical  and  histo-
pathologic  factors  [13-16].  Therefore,  the  goals  of  this  study 
were  to  identify  these  prognostic  factors  and  to  evaluate  the 
association between histopathologic and molecular markers. A 
multitude  of  histopathologic  factors  associated  with  survival 
have  been  described  in  the  literature  through  retrospective 
series  studies.  Harpole  et  al.  [3]  identified  vascular  invasion, 
visceral  pleural  invasion,  a  high  mitotic  index,  and  a  tumor 
size  greater  than  3  cm  as  risk  factors  associated  with  re-
currence  in  289  resected  stage  I  lung  cancer  patients.  In  this 
study, histological factors including tumor size, differentiation, 
and T stage were identified as significant factors. The degree 
of differentiation of the primary tumor is known to be a sig-
nificant  prognostic  factor  and  poor  differentiated  tumors  are 
defined as negative prognostic factors in patients with stage I 
NSCLC [17]. Tumor size was rearranged in the 7th edition of 
the  guidelines  of  the  AJCC  and  this  detailed  size  rearrange-
ment was more effective in predicting recurrence than the 6th 
edition guidelines (data not shown). Although observation da-
ta based on clinical and histopathologic description aids in di-
viding  patients  into  risk  groups,  much  variation  exists  in  the 
interpretation  of  these  qualitative  variables.  Therefore,  many 
molecular biologic markers have recently been studied in lung Sukki Cho, et al
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Table 5.  Association between histopathologic and molecular factors
Factors Variables Univariate  analysis
Age  (yr)
Sex
Location
Differentiation
Histology
Visceral  pleural  invasion
Necrosis
Tumor  size  (cm)
T  stage
TTF-1
EGFR
E-cadherin
Survivin
＜65,  ≥65
Male/female
Central/periphery/mid
Good/moderate/poor
SCC/AC/BAC
Absent/present
Absent/present
≤2,  2＜ &  ≤3,  3＜ &  ≤5,  5＜ &  ≤7,  ＞7
1/2
Negative/positive
Normal/overexpressed
Loss/preserved
Normal/overexpressed
0.497
0.332
0.136
0.026
0.402
0.000
0.284
0.210
0.023
0.304
0.924
0.332
0.049
SCC=squamous  cell  carcinoma;  AC=adenocarcinoma;  BAC=bronchioalveolar  carcinoma;  TTF-1=thyroid  transcription  factor  1;  EGFR= 
epidermal  growth  factor  receptor.
Fig. 1. Kaplan-Meier analysis of disease free survival for (A) visceral pleural invasion (VPI)  (B) T-factor (C) differentiation, (D) survivin.Poor Prognostic Factors in Surgically Resected Stage I Non-small Cell Lung Cancer
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Table 6. Multivariate analysis of disease-free survival by Cox pro-
portional hazards regression model
Variables HR 95%  CI p-value
T  stage
Visceral  pleural  invasion
TTF-1  negative
Survivin  overexpression
Poor  differentiation
1.729
2.532
0.440
2.212
3.147
0.365−8.199
0.750−8.549
0.157−1.232
1.014−5.652
1.296−7.639
0.490
0.135
0.118
0.045
0.011
HR=hazard  ratio;  CI=confidence  interval;  TTF-1=thyroid  tran-
scription  factor  1.
cancer  to  determine  their  prognostic  importance.  Gene  copy 
number  and  mutation  analyses  are  now  being  explored  in 
prospective clinical studies in enriched populations. These as-
says  are  very  promising,  but  they  are  costly  and  are  not 
widely  available.  In  contrast,  protein  expression  studies  by 
immunohistochemistry  are  rapid,  reproducible,  and  routinely 
performed  in  many  hospitals.  During  the  last  decade,  the  ag-
gressive  phenotypes  of  lung  cancer  have  been  characterized 
by  a  number  of  molecular  abnormalities,  so  multiple  algo-
rithms  were  created  based  on  relative  protein  expression  pro-
files  using  up  to  15  factors  with  possible  significance.
In this study, we have evaluated factors such as TTF-1 and 
surviving,  which  have  not  been  extensively  studied.  TTF-1  is 
mainly  expressed  in  the  thyroid  and  lung  during  embryo-
genesis, and it plays a physiological role in their development 
and  morphogenesis.  Positive  TTF-1  staining  by  immunohisto-
chemistry  has  been  described  in  25%  to  80%  of  primary  ad-
nenocarcinoma;  however,  the  vast  majority  of  squamous  cell 
carcinoma  of  the  lung  lacks  TTF-1  expression  [7].  In  our 
study, TTF-1 positivity was 8.7% in squamous cell carcinoma 
and  66.7%  in  adenocarcinoma.  TTF-1  positive  adenocar-
cinoma  had  significant  relationships  with  the  prevalence  of 
female,  nonsmoker,  negative  staining  of  p53,  less  frequent 
retinoblastoma  protein  loss,  and  preserved  expression  of  p27 
[18].  Yatabe  et  al.  [19]  demonstrated  that  TTF-1  was  con-
sistently  expressed  during  development  and  this  pattern  was 
preserved  in  transformed  cells  and  metastatic  lymph  node. 
Expression  was  not  affected  by  the  differentiation  state. 
However,  Anagnostou  et  al.  [7]  showed  that  patients  with 
stage  I  adenocarcinoma  with  TTF-1  expression  had  a  longer 
median overall survival than those without expression and re-
vealed  TTF1-expression  as  an  independent  lower  risk  factor 
for  patients  with  stage  I  adenocarcinoma.
EGFR  is  a  member  of  the  receptor  tyrosine  kinase  (TK) 
family, and TKs regulate signaling pathways that control crit-
ical  cellular  activities  [20].  The  clinical  importance  of  EGFR 
has  increased  with  the  development  of  EGFR  TK  inhibitors 
(TKI).  EGFR  mutations  were  observed  more  frequently  in 
women,  never-smokers,  and  in  adenocarcinoma,  and  EGFR 
TKIs  were  more  effective  in  patients  with  EGFR  mutations. 
Suzuki et al. [21] compared mutation with expression and re-
ported  that  EGFR  overexpression  was  significantly  higher  in 
cases  where  EGFR  mutation  was  positive  rather  than  nega-
tive.  In  this  study,  EGFR  overexpression  was  more  common 
in squamous cell carcinoma, men, and ever-smokers, which is 
in  contrast  with  the  findings  of  EGFR  mutation.  Therefore, 
the exact mechanism remains unclear whether EGFR mutation 
is  the  major  contributor  to  EGFR  overexpression.
E-cadherin  and  catenins  are  components  of  the  adherens 
junction protein, with crucial roles in maintaining intercellular 
junctions  in  epithelial  cells;  reduced  E-cadherin  expression 
could  potentially  affect  tumor  differentiation,  metastasis,  and 
prognosis [10,11]. Although the number of patients who have 
demonstrated  the  loss  of  E-cadherin  is  small,  it  still  repre-
sents  a  significant  prognostic  factor.
Survivin is a recently identified protein that functions as an 
inhibitor of apoptosis, suppressing programmed cell death and 
regulating  cell  division.  The  expression  of  survivin  is  un-
detectable  or  found  at  very  low  levels  in  normal  tissues  but 
at  high  levels  in  various  malignancies  and  also  embryonic 
and  fetal  tissues  [22].  The  overexpression  of  survivin  may 
overcome  apoptotic  checkpoints  and  promote  aberrant  pro-
gression of the transformed cell through mitosis. A high level 
of survivin expression in malignancies is considered to be an 
important  indicator  of  poor  prognosis  and  associated  with 
high  tumor  grade,  tumor  progression,  and  chemoresistance 
[23].  Survivin  staining  was  detected  in  both  the  nucleus  and 
the  cytoplasm  of  NSCLC.  However,  it  was  shown  that  nu-
clear survivin, rather than cytoplasmic staining, was predictive 
of  poor  survival  in  patients  with  NSCLC  and  esophageal 
cancer.  Shinohara  et  al.  [8]  showed  patients  who  had  nuclear 
staining  for survivin had a significantly increased  risk of  dis-
ease  recurrence  and  concluded  that  the  nuclear  presence  of Sukki Cho, et al
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survivin  may  be  an  independent  biomarker  for  disease  re-
currence and overall survival in patients with resected stage I 
a n d  I I  N S C L C .  A t i k c a n  e t  a l .  [ 2 4 ]  e v a l u a t e d  t h e  p r o g n o s t i c  
significance  of  both  nuclear  and  cytoplasmic  survivin  ex-
pression in NSCLC and showed that cytoplasmic staining was 
found  to  be  significantly  increased  in  squamous  cell  carcino-
ma  and  that  nuclear  survivin  expression  might  predict  prog-
nosis  in  NSCLC,  whereas  cytoplasmic  survivin  has  no  prog-
nostic  significance.
This  study  had  limitations.  First,  immunohistochemical 
scoring  is  at  best  a  semi-quantitative  exercise  for  which  no 
standard  criteria  have  yet  been  proposed  or  adopted.  The 
scoring  methods  that  have  been  used  include  estimating  the 
grade  of  staining  intensity,  the  percentage  of  tumor  cells 
stained,  the  cellular  localization  of  the  antigen,  and  systems 
that  combined  these  parameters.  Second,  a  more  important 
confusion  is  the  method  of  determining  cut-offs  for  dichoto-
mizing  scores  in  log-rank  tests.  Cut-offs  are  often  arbitrary 
and  are  sometimes  selected  to  obtain  the  desired  effect  using 
the  minimum  p-value  approach.  Therefore,  different  anti-
bodies  and  grading  systems  should  also  be  taken  into  ac-
count;  the  counting  of  positive  tumor  cells  and  grading  of 
staining  intensity  may  be  subject  to  interobserver  variability, 
which  should  be  evaluated.
CONCLUSION
In  resected  stage  I  non-small  cell  lung  cancer,  poor  differ-
entiation  and  survivin  overexpression  have  been  identified  as 
independent  predictors  of  poor  disease-free  survival.
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